Encorafenib

Definition

An orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.

Also known as Braftovi, ENCORAFENIB, LGX 818, LGX-818, LGX818 — per NCIT

Also identified as

• ATC L01EC03 per RXNORM
• NCIT NCIT:C98283 per NCIT
• SCTID 772091004 per RXNORM
• SCTID 772201002 per RXNORM
• UNII 8L7891MRB6 per RXNORM

Indications